Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health ESA Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentZing HealthPolicy 5278-D

    Medicare Part B Step Therapy Erythropoiesis Stimulating Agents

    Customize your policy alerts

    Sign up for zing_health Policy 5278-D alerts

    Get alerted when Policy 5278-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Part B coverage of preferred and non-preferred erythropoiesis-stimulating agents, including biosimilar-first preferences and prior authorization exceptions for non-preferred products.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Erythropoiesis Stimulating Agents
    Policy CodePolicy 5278-D
    Change TypeNo material clinical or coverage changes
    Effective DateNot specified
    Next Review DateNot specified
    Key ActionUse Aranesp or Retacrit before requesting a non-preferred product, unless qualifying prior use or documented exception criteria apply.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Preferred agents
    3Non-preferred agents
    365 daysPrior-treatment lookback
    3Covered indications

    Covered Indications and Product Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Anemia due to chronic kidney disease — Epogen or Procrit

    Coverage for Epogen or Procrit is provided when either of the following criteria is met.

    ONE of

    • Prior treatment

      • The member has received treatment with Epogen or Procrit in the past 365 days.Past 365 days
    • Preferred-product exception

      • The member has a documented intolerable adverse event with Retacrit, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.

        A known adverse reaction to the active ingredient for both the reference product and biosimilar product does not qualify as the specified Retacrit exception.

      • The member has a documented inadequate response or intolerable adverse event with the preferred product Aranesp.

    Anemia due to chronic kidney disease — Mircera

    Coverage for Mircera is provided when either of the following criteria is met.

    ONE of

    • Prior treatment

      • The member has received treatment with Mircera in the past 365 days.Past 365 days
    • Failure or intolerance of both preferred products

      • The member has a documented inadequate response or intolerable adverse event with Aranesp.
      • The member has a documented inadequate response or intolerable adverse event with Retacrit.

    Anemia due to myelosuppressive chemotherapy in cancer

    Coverage for Epogen or Procrit is provided when either of the following criteria is met.

    ONE of

    • Prior treatment

      • The member has received treatment with Epogen or Procrit in the past 365 days.Past 365 days
    • Preferred-product exception

      • The member has a documented intolerable adverse event with Retacrit, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.

        A known adverse reaction to the active ingredient for both the reference product and biosimilar product does not qualify as the specified Retacrit exception.

      • The member has a documented inadequate response or intolerable adverse event with the preferred product Aranesp.

    Anemia due to zidovudine in HIV infection and reduction of allogeneic RBC transfusions

    Coverage for Epogen or Procrit is provided when either of the following criteria is met.

    ONE of

    • Prior treatment

      • The member has received treatment with Epogen or Procrit in the past 365 days.Past 365 days
    • Retacrit intolerance exception

      • The member has a documented intolerable adverse event with Retacrit, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.

        A known adverse reaction to the active ingredient for both the reference product and biosimilar product does not qualify as the specified Retacrit exception.

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Exception Request for Non-Preferred Products

    A prior authorization request is required when requesting a non-preferred erythropoiesis-stimulating agent. The request must explain the clinical circumstances that exclude use of the preferred product and support a qualifying exception.

    • Identify the requested non-preferred product and the applicable FDA-approved indication.
    • Submit clinical documentation supporting the exception, including prior treatment history or documented inadequate response or intolerable adverse events when applicable.
    Prior Authorization

    Preferred Products May Require Prior Authorization

    Preferred products may still require clinical prior authorization review. Meeting the preferred-product step does not eliminate other applicable clinical review requirements.

    • Preferred products: Aranesp (darbepoetin alfa) and Retacrit (epoetin alfa-epbx).
    Step Therapy

    Preferred Products First

    Use the preferred products first before requesting an applicable non-preferred product, subject to a qualifying clinical exception. Step therapy applies in addition to any applicable NCD, LCD, or Medicare Part B utilization management program.

    • Preferred products: Aranesp or Retacrit.
    • Non-preferred products: Epogen, Mircera, and Procrit.
    • The program applies when requesting treatment for an FDA-approved indication of the preferred product.
    Documentation Required

    Document Prior Treatment History

    When relying on prior use as the exception, document that the member received treatment with the requested product within the past 365 days.

    • For Epogen or Procrit requests, document prior treatment with Epogen or Procrit within the past 365 days.
    • For Mircera requests, document prior treatment with Mircera within the past 365 days.
    Documentation Required

    Document the Preferred-Product Exception

    When the request is not supported by qualifying prior use, document the required inadequate response or intolerable adverse event with the applicable preferred products. An adverse event must be documented as intolerable and, where specified, must not be an expected adverse event attributable to the active ingredient as described in the prescribing information.

    • For Epogen or Procrit in chronic kidney disease or myelosuppressive chemotherapy in cancer: document an intolerable adverse event with Retacrit that is not an expected active-ingredient adverse event, plus an inadequate response or intolerable adverse event with Aranesp.
    • For Mircera in chronic kidney disease: document an inadequate response or intolerable adverse event with both Aranesp and Retacrit.
    • For Epogen or Procrit for zidovudine-associated anemia in patients with HIV infection or to reduce the need for allogeneic RBC transfusions: document the specified intolerable Retacrit adverse event that is not an expected active-ingredient adverse event.
    Documentation Required

    Identify the Indication and Requested Product

    The request must identify both the FDA-approved indication being treated and the requested erythropoiesis-stimulating agent.

    • Indications addressed include anemia due to chronic kidney disease; anemia due to myelosuppressive chemotherapy in cancer; and anemia due to zidovudine in patients with HIV infection or to reduce the need for allogeneic RBC transfusions.
    • Requested agents include Epogen, Procrit, and Mircera, as applicable.
    Denial Risk

    Non-Preferred Product Without an Exception

    A non-preferred product is not covered without an approved clinical exception. Coverage is limited to situations in which the preferred product is excluded by qualifying clinical circumstances or applicable prior treatment history.

    • Submit prior authorization documentation supporting the applicable exception criteria.
    • Without an approved exception, requests for non-preferred Epogen, Mircera, or Procrit may be denied.
    Denial Risk

    Insufficient Documentation May Result in Denial

    Incomplete step-therapy documentation may result in denial. Requests can be denied when the record does not establish prior treatment with the requested product within the past 365 days or, when required, an inadequate response or intolerable adverse event with the applicable preferred products.

    • Document the relevant product, dates of prior treatment, and clinical response.
    • Document the specific adverse event, its intolerability, and whether it is an expected active-ingredient reaction when that distinction is required.
    • For criteria requiring both preferred products or multiple clinical findings, documentation must support each required element.

    Policy Scope and Clinical Context

    This policy applies to Medicare Part B erythropoiesis-stimulating agents used for FDA-approved indications. Preferred products are Aranesp (darbepoetin alfa) and Retacrit (epoetin alfa-epbx); non-preferred products are Epogen (epoetin alfa), Mircera (methoxy polyethylene glycol-epoetin beta), and Procrit (epoetin alfa).

    Covered indications include anemia due to chronic kidney disease, anemia due to myelosuppressive chemotherapy in cancer, anemia due to zidovudine in patients with HIV infection, and reduction of the need for allogeneic red blood cell transfusions. Non-preferred products are subject to preferred-product sequencing and clinical exception review. Step therapy applies in addition to applicable Medicare coverage and utilization-management requirements.

    Program and Exception Definitions

    Advanced Biosimilars First
    Program alignmentMedicare Part B Advanced Biosimilars First
    PurposeEstablishes preferred-product sequencing for erythropoiesis-stimulating agents
    Non-preferred product reviewCoverage for a non-preferred product is considered through an exception process based on clinical circumstances that would exclude use of the preferred product or on previous use of a product
    Clinical exception
    DefinitionA clinical exception is the review process used to determine whether a non-preferred product may be covered
    Clinical basisThe review evaluates clinical circumstances that would exclude use of the preferred product
    Previous product useThe review may also consider the member’s previous use of a product

    Initial Therapy Eligibility

    Initial therapy eligibility

    The program applies when treatment is requested for an FDA-approved indication of the preferred product.

    ALL of the following

    • The requested treatment must be for an indication that is FDA-approved for the preferred product.

    Product-Specific Step Requirements

    StepRequested productQualifying pathway
    1Epogen or ProcritCoverage is provided when the member has received the requested product within the past 365 days, or when both requirements are met: a documented intolerable adverse event with Retacrit that was not an expected adverse event attributed to the active ingredient, and a documented inadequate response or intolerable adverse event with Aranesp.
    StepRequested productQualifying pathway
    2MirceraCoverage is provided when the member has received Mircera within the past 365 days, or has a documented inadequate response or intolerable adverse event with both preferred products, Aranesp and Retacrit.

    Preferred Epoetin Alfa Product

    Billing Rule

    Retacrit is preferred over Epogen and Procrit

    Retacrit is preferred over the non-preferred epoetin alfa products Epogen and Procrit.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy Erythropoiesis Stimulating Agents
    Policy CodePolicy 5278-D
    Change TypeNo material clinical or coverage changes
    Effective DateNot specified
    Next Review DateNot specified
    Key ActionUse Aranesp or Retacrit before requesting a non-preferred product, unless qualifying prior use or documented exception criteria apply.
    SourceLink
    On This Page
    Covered Indications and Product CriteriaPrior Authorization and Documentation RequirementsPolicy Scope and Clinical ContextProgram and Exception DefinitionsInitial Therapy EligibilityProduct-Specific Step RequirementsPreferred Epoetin Alfa Product